Qing Li

7PUBLICATIONS
6CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 06, 2025
An exploration of the initiation time and patient selection of PD-1 inhibitors/PD-1 inhibitors combined with chemotherapy as salvage therapy in R/R DLBCL patients after anti-CD19-CAR T-cell therapy.

|Apr 23, 2024
Persistent Cytopenia After CD19 CAR T Therapy in Relapsed/Refractory DLBCL Patients Could Be a Predictor of Efficacy and Side Effects.

Jingyi Li, Juan Mu, Jia Wang

|Mar 08, 2024
Efficacy and side effects of anti-CD19 CAR T-cell therapy in patients with relapsed/refractory gastrointestinal lymphoma.

Yi Li Jiang, Juan Mu, Rui Cui

|Mar 07, 2023
Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant.

Qing Li, Cuicui Lyu, Meijing Liu

|Feb 23, 2022
Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden.

Juan Mu, Haobin Deng, Cuicui Lyu

|Apr 02, 2020
Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia.

Jia Wang, Nan Mou, Zhenxing Yang

Pageof 2

Frequent Collaborators

4 joint publications

Qi Deng

3 joint publications

Jia Wang

3 joint publications

Juan Mu

2 joint publications

Yili Jiang